Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets

Bone is one of the most preferential target site for cancer metastases, particularly for prostate, breast, kidney, lung and thyroid primary tumours. Indeed, numerous chemical signals and growth factors produced by the bone microenvironment constitute factors promoting cancer cell invasion and aggression. After reviewing the different theories proposed to provide mechanism for metastatic progression, we report on the gene expression profile of bone-seeking cancer cells. We also discuss the cross-talk between the bone microenvironment and invading cells, which impacts on the tumour actions on surrounding bone tissue. Lastly, we detail therapies for bone metastases. Due to poor prognosis for patients, the strategies mainly aim at reducing the impact of skeletal-related events on patients’ quality of life. However, recent advances have led to a better understanding of molecular mechanisms underlying bone metastases progression, and therefore of novel therapeutic targets.

[1]  N. Melis,et al.  Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial , 2018, Journal of tissue engineering and regenerative medicine.

[2]  Prashanth Panta,et al.  MTA1 expression in human cancers - Clinical and pharmacological significance. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  M. Szendrői,et al.  Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine , 2017, EFORT open reviews.

[4]  M. Callstrom,et al.  Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours. , 2017, Clinical radiology.

[5]  J. Scimeca,et al.  The multiple therapeutic applications of miRNAs for bone regenerative medicine. , 2017, Drug discovery today.

[6]  A. Zygogianni,et al.  The role of radiotherapy in bone metastases: A critical review of current literature , 2017, European journal of cancer care.

[7]  M. Chwistek,et al.  Recent advances in understanding and managing cancer pain , 2017, F1000Research.

[8]  J. Laredo,et al.  Vertebroplasty and interventional radiology procedures for bone metastases. , 2017, Joint, bone, spine : revue du rhumatisme.

[9]  W. Fraser,et al.  miR-16 is highly expressed in Paget's associated osteosarcoma. , 2017, Endocrine-related cancer.

[10]  I. Berindan‐Neagoe,et al.  How to Diagnose and Treat a Cancer of Unknown Primary Site. , 2017, Journal of gastrointestinal and liver diseases : JGLD.

[11]  William H. Bisson,et al.  Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions , 2017, Cellular and molecular gastroenterology and hepatology.

[12]  C. Antonescu,et al.  Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer , 2017, International journal of molecular sciences.

[13]  J. Bouler,et al.  Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases. , 2016, Biochemical pharmacology.

[14]  I. Krizbai,et al.  Small Vessels – Big Problems : Novel Insights into Microvascular Mechanisms of Diseases When the endothelium scores an own goal : endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition , 2016 .

[15]  M. Taketo,et al.  The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis , 2016, International journal of molecular sciences.

[16]  K. Miyazono,et al.  Mechanisms of action of bone morphogenetic proteins in cancer. , 2016, Cytokine & growth factor reviews.

[17]  D. Oupický,et al.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery , 2016, Current Pharmacology Reports.

[18]  C. Van Noorden,et al.  Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. , 2015, Seminars in cancer biology.

[19]  E. Terpos,et al.  Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. , 2015, BoneKEy reports.

[20]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[21]  Sang Hyuk Park,et al.  VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia , 2015, Annals of Hematology.

[22]  Yihong Wan,et al.  New therapeutic targets for cancer bone metastasis. , 2015, Trends in pharmacological sciences.

[23]  Xiaoxiao Hu,et al.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[24]  S. Spektor,et al.  Potential neurotoxic effects of polymethylmethacrylate during cranioplasty , 2015, Journal of Clinical Neuroscience.

[25]  Duane D. Miller,et al.  Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. , 2014, Blood.

[26]  A. Sudo,et al.  Anti-Tumor Necrosis Factor Therapy Inhibits Lung Metastasis in an Osteosarcoma Cell Line , 2014, Oncology.

[27]  D. Heymann,et al.  Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. , 2014, Bone.

[28]  M. van Driel,et al.  Cancer and bone: a complex complex. , 2014, Archives of biochemistry and biophysics.

[29]  Lin He,et al.  miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2 , 2014, Nature.

[30]  G. Tortora,et al.  CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors , 2014, BioMed research international.

[31]  D. Heymann,et al.  Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration , 2014, BMC Cancer.

[32]  J. Bouler,et al.  Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? , 2014, Drug discovery today.

[33]  D. Schadendorf,et al.  The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling , 2014, Front. Oncol..

[34]  F. de Marinis,et al.  Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies , 2014, Therapeutic advances in medical oncology.

[35]  A. Godwin,et al.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. , 2014, Critical reviews in oncology/hematology.

[36]  T. Vanderah,et al.  Cancer-induced bone pain: Mechanisms and models , 2013, Neuroscience Letters.

[37]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[38]  N. Gronich,et al.  Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates , 2013, Nature Reviews Clinical Oncology.

[39]  H. Zeng,et al.  The role of neural-related factors in the metastasis of the gastrointestinal cancer. , 2013, Journal of cancer research and therapeutics.

[40]  R. Wedin,et al.  Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. , 2013, Surgical oncology.

[41]  M. Heymann,et al.  Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.

[42]  P. Clézardin Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. , 2013, BoneKEy reports.

[43]  X. Yao,et al.  An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. , 2013, Asian journal of andrology.

[44]  M. Suarez‐Almazor,et al.  Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. , 2013, Cancer treatment reviews.

[45]  B. Williams,et al.  Skeletal metastasis: treatments, mouse models, and the Wnt signaling , 2013, Chinese journal of cancer.

[46]  F. Mami-Chouaib,et al.  Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. , 2012, Cancer research.

[47]  J. Mönkkönen,et al.  In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement , 2012, Clinical Cancer Research.

[48]  C. Heldin,et al.  Induction of epithelial-mesenchymal transition by transforming growth factor β. , 2012, Seminars in cancer biology.

[49]  A. Viola,et al.  The pros and cons of chemokines in tumor immunology. , 2012, Trends in immunology.

[50]  K. Gelmon,et al.  Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. , 2012, Current oncology.

[51]  P. Lara,et al.  Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. , 2012, Surgical oncology.

[52]  J. Thariat,et al.  [Improvements of ablative local treatments modify the management of the oligometastatic disease]. , 2012, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[53]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[54]  G. Morgan,et al.  Effects of bone-targeted agents on cancer progression and mortality. , 2012, Journal of the National Cancer Institute.

[55]  G. Bernardini,et al.  Chemokines and NK cells: Regulators of development, trafficking and functions , 2012, Immunology Letters.

[56]  J. Cunningham,et al.  Connective tissue growth factor in tumor pathogenesis , 2012, Fibrogenesis & tissue repair.

[57]  T. Guise,et al.  The role of TGF-β in bone metastasis: novel therapeutic perspectives. , 2012, BoneKEy reports.

[58]  T. Hahn,et al.  The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis , 2012, Cancer Immunology, Immunotherapy.

[59]  A. Loubat,et al.  Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes. , 2012, Biochemical pharmacology.

[60]  D. Lyden,et al.  Megakaryocytes, malignancy and bone marrow vascular niches , 2012, Journal of thrombosis and haemostasis : JTH.

[61]  R. Tenaglia,et al.  Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review , 2011, Central European journal of urology.

[62]  J. Kotzerke,et al.  Internal radiotherapy of painful bone metastases. , 2011, Methods.

[63]  J. Mönkkönen,et al.  High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. , 2011, Cancer research.

[64]  M. Barbagallo,et al.  Physiology of the aging bone and mechanisms of action of bisphosphonates , 2011, Biogerontology.

[65]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[66]  J. V. Von Roenn,et al.  American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of Oncology Practice.

[67]  H. Votavova,et al.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome , 2011, European Journal of Human Genetics.

[68]  G. van der Pluijm,et al.  Targeted therapy options for treatment of bone metastases; beyond bisphosphonates. , 2010, Current pharmaceutical design.

[69]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[70]  Y. DeClerck,et al.  Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.

[71]  P. Allavena,et al.  The chemokine system in cancer biology and therapy. , 2010, Cytokine & growth factor reviews.

[72]  S. Koscielny,et al.  Parallel progression of tumour and metastases , 2010, Nature Reviews Cancer.

[73]  J. Chirgwin,et al.  The critical role of the bone microenvironment in cancer metastases , 2009, Molecular and Cellular Endocrinology.

[74]  B. Schaller,et al.  Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. , 2009, Cancer letters.

[75]  Ajit Varki,et al.  Molecular basis of metastasis. , 2009, The New England journal of medicine.

[76]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[77]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[78]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[79]  G. van der Pluijm,et al.  Osteotropic cancers: from primary tumor to bone. , 2009, Cancer letters.

[80]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[81]  C. Bünger,et al.  Molecular treatment strategies and surgical reconstruction for metastatic bone diseases. , 2008, Cancer treatment reviews.

[82]  Harold Varmus,et al.  Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.

[83]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[84]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[85]  J. Chirgwin,et al.  Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.

[86]  Michael Koutsilieris,et al.  Mechanisms of bone metastasis in prostate cancer: clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[87]  Tracy M Handel,et al.  Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. , 2008, The Biochemical journal.

[88]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[89]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[90]  F. Pépin,et al.  Osteoactivin Promotes Breast Cancer Metastasis to Bone , 2007, Molecular Cancer Research.

[91]  D. Theodorescu,et al.  The role of PTEN in prostate cancer cell tropism to the bone micro-environment. , 2007, Carcinogenesis.

[92]  J. Chiras,et al.  Interventional radiology in bone metastases , 2007, European journal of cancer care.

[93]  R. Kaplan,et al.  Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.

[94]  M. Charbonneau,et al.  Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression* , 2006, Journal of Biological Chemistry.

[95]  T. Luger,et al.  Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. , 2006, Cancer research.

[96]  B. Rollins,et al.  Inflammatory chemokines in cancer growth and progression. , 2006, European journal of cancer.

[97]  Wei Wei,et al.  Metastatic patterns in adenocarcinoma , 2006, Cancer.

[98]  D. d'Ambrosio Regulatory T cells: how do they find their space in the immunological arena? , 2006, Seminars in cancer biology.

[99]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  Antoinette Wetterwald,et al.  Molecular and Biological Mechanisms of Bone Metastasis , 2005 .

[101]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[102]  P. Clézardin,et al.  Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. , 2005, Cancer research.

[103]  M. Miyasaka,et al.  Chemokines in tumor progression and metastasis , 2005, Cancer science.

[104]  T. Yoneda,et al.  Crosstalk between cancer cells and bone microenvironment in bone metastasis. , 2005, Biochemical and biophysical research communications.

[105]  J. Votaw,et al.  Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.

[106]  L. Rosen,et al.  Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. , 2004, Clinical lung cancer.

[107]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[108]  Naoto T Ueno,et al.  Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[110]  P. Clézardin,et al.  Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity* , 2003, Journal of Biological Chemistry.

[111]  L. Puricelli,et al.  GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity. , 2003, Oncology reports.

[112]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[114]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[115]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[116]  C. Sotiriou,et al.  Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. , 2001, Cancer letters.

[117]  G. Clayman,et al.  Chemokines in cancer , 2001, Expert Reviews in Molecular Medicine.

[118]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[119]  G. Byrne,et al.  Bone metastasis in breast cancer: the role of parathyroid hormone related protein. , 1999, Surgical oncology.

[120]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[121]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[122]  R. Coleman Skeletal complications of malignancy , 1997, Cancer.

[123]  Jane M. Moseley,et al.  Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? , 1993, Molecular and cellular endocrinology.

[124]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[125]  S. Koscielny,et al.  Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.

[126]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[127]  V. P. Collins,et al.  Observations on growth rates of human tumors. , 1956, The American journal of roentgenology, radium therapy, and nuclear medicine.

[128]  James Ewing,et al.  Neoplastic Diseases: A Treatise on Tumours , 1928, The Indian Medical Gazette.

[129]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[130]  P. ten Dijke,et al.  Targeting TGF-β Signaling in Cancer. , 2017, Trends in cancer.

[131]  U. Weidle,et al.  Molecular Mechanisms of Bone Metastasis. , 2016, Cancer genomics & proteomics.

[132]  M. Chaudhry,et al.  Evaluation of osseous metastasis in bone scintigraphy. , 2015, Seminars in nuclear medicine.

[133]  M. David,et al.  Pleiotropic activity of lysophosphatidic acid in bone metastasis. , 2013, Biochimica et biophysica acta.

[134]  N. Hemdan Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. , 2013, Immunology letters.

[135]  J. Thariat,et al.  [Improvements of ablative local treatments modify the management of the oligometastatic disease]. , 2012, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[136]  T. Yoneda,et al.  Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. , 2011, Bone.

[137]  T. Guise,et al.  TGF-β in cancer and bone: implications for treatment of bone metastases. , 2011, Bone.

[138]  T. Guise Antitumor effects of bisphosphonates: promising preclinical evidence. , 2008, Cancer treatment reviews.

[139]  C. Herzog,et al.  Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). , 2008, Expert opinion on investigational drugs.

[140]  P. Camparo,et al.  [Molecular aspects of prostate cancer: recent data from the literature]. , 2007, Bulletin du cancer.

[141]  W. Gerald,et al.  Identifying site-specific metastasis genes and functions. , 2005, Cold Spring Harbor symposia on quantitative biology.

[142]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[143]  K. Mohammad,et al.  Endothelins in bone cancer metastases. , 2004, Cancer treatment and research.

[144]  G. Klein,et al.  Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. , 1996, Folia biologica.